{
    "name": "linaclotide",
    "comment": "Rx",
    "other_names": [
        "Linzess"
    ],
    "classes": [
        "IBS Agents",
        "Gastrointestinals",
        "Guanylate Cyclase-C Agonists"
    ],
    "source": "https://reference.medscape.com/drug/linzess-linaclotide-999768",
    "pregnancy": {
        "common": [
            "Linaclotide and its active metabolite are negligibly absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure",
            "Insufficient data available data on use in pregnant women to inform any drug-associated risk for major birth defects and miscarriage"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "No effects on embryofetal development were observed with oral administration of linaclotide in rats and rabbits during organogenesis at doses much higher than the maximum recommended human dosage",
                    "Severe maternal toxicity associated with effects on fetal morphology were observed in mice"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Linaclotide and its active metabolite were not detected in the milk of lactating women; in adults, concentrations of linaclotide and its active metabolite were below the limit of quantitation in plasma following multiple doses of the drug",
            "Maternal use of the drug is not expected to result in exposure to the drug or its active metabolite in breastfed infants; there is no information on effects on milk production; consider developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from the drug or from the underlying maternal condition",
            "No lactation studies in animals have been conducted",
            "Unknown whether negligible systemic absorption of linaclotide by adults will result in a clinically relevant exposure to breastfed infants"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Contraindicated in pediatric patients aged <2 years",
                "In nonclinical studies in neonatal mice, oral administration of a single, clinically relevant adult dose of linaclotide caused deaths due to dehydration"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Patients aged <2 years due to risk of serious dehydration",
                "Known or suspected mechanical gastrointestinal obstruction"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Pediatric risk",
                    "description": [
                        "Contraindicated in patients <2 years of age",
                        "In neonatal mice, fluid secretion increased because of GC-C agonism resulting in mortality within the first 24 hr due to dehydration",
                        "There was no age-dependent trend in GC-C intestinal expression in a clinical study of children 2 to <18 years of age; there are insufficient data available on GC-C intestinal expression in children aged <2 years to assess the risk of developing diarrhea and its potentially serious consequences in these patients",
                        "Safety and efficacy in patients aged <18 years not established"
                    ]
                },
                {
                    "type": "Diarrhea",
                    "description": [
                        "Diarrhea was the most common adverse reaction in clinical trials",
                        "In postmarketing reports, severe diarrhea associated with dizziness, syncope, hypotension and electrolyte abnormalities (hypokalemia and hyponatremia) requiring hospitalization or IV fluid administration have been reported",
                        "If severe diarrhea occurs, suspend dosing and rehydrate"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "20"
        },
        {
            "name": "Diarrhea",
            "percent": "16-22"
        },
        {
            "name": "Abdominal pain",
            "percent": "7"
        },
        {
            "name": "Flatulence",
            "percent": "4"
        },
        {
            "name": "Headache",
            "percent": "4"
        },
        {
            "name": "Viral gastroenteritis",
            "percent": "3"
        },
        {
            "name": "Abdominal distension",
            "percent": "2"
        },
        {
            "name": "Severe diarrhea",
            "percent": "2"
        },
        {
            "name": "Defecation urgency",
            "percent": "2"
        },
        {
            "name": "Fecal incontinence",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Gastroesophageal reflux disease",
            "percent": "2"
        },
        {
            "name": "Abdominal pain",
            "percent": "7"
        },
        {
            "name": "Flatulence",
            "percent": "6"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "5"
        },
        {
            "name": "Sinusitis",
            "percent": "3"
        },
        {
            "name": "Abdominal distension",
            "percent": "1-3"
        },
        {
            "name": "Defecation urgency",
            "percent": "2"
        },
        {
            "name": "Fecal incontinence",
            "percent": "2"
        },
        {
            "name": "Dyspepsia",
            "percent": "2"
        },
        {
            "name": "Viral gastroenteritis",
            "percent": "2"
        }
    ]
}